Adjuvant radiotherapy for stage I endometrial cancer

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 4, 2012, Pages

  Kong, Anthony ^a   Johnson, Nick ^b   Kitchener, Henry C ^c   Lawrie, Theresa A ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT RADIOTHERAPY; BRACHYTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; DIARRHEA; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FECES INCONTINENCE; GASTROINTESTINAL TOXICITY; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; OVARIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINE INCONTINENCE; VAGINAL INTRACAVITARY BRACHYTHERAPY; ADJUVANT THERAPY; ENDOMETRIUM TUMOR; FEMALE; META ANALYSIS; METHODOLOGY; PATHOLOGY; SURVIVAL;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84861935739     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003916.pub4     Document Type: Review

References (78)

1. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics and Gynecology 1980;56(4):419-27.
2. Onsrud M, Kolstad P, Normann T. Postoperative external pelvic irradiation in carcinoma of the corpus stage I: a controlled clinical trial. Gynecologic Oncology 1976;4(2):222-31.
3. ASTEC/EN.5 Study Group: Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. The Lancet 2009;373(9658):137-46.
4. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. The Lancet 2009;373(9658):125-36.
5. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. Erratum to “A phase III. trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study” [Gynecol. Oncol. 92 (2004) 744-751]. Gynecologic Oncology 2004;94(1):241-2.
6. Keys HM, Roberts JA, Brunetto VL, Ziano RJ, Spirtos NM, Bloss JD, et al. A phase III. trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology 2004;92(3):744-51.
7. von Gruenigen VE, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR. Treatment effects, disease recurrence and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer 2006;107(12):2786-91.
8. Burger MP, Mol BW. Treatment for patients with stage-1 endometrial carcinoma (comment on: Lancet. 2000 Apr 22;355(9213):1404-11. Lancet 2000;356(9232):853-4.
9. Creutzberg CL, Koper PCM, Lybeert MLM, Warlam Rodenhuis CC. A prospective randomized trial to assess the effect of adjuvant radiotherapy in medium risk pT1 endometrial carcinoma. International Journal of Gynecological Cancer 1995;5 (Supl.1):2 Abstract 8.
10. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. International Journal of Radiation Oncology, Biology, Physics 2011;15(81):e631-8.
11. Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404-11.
12. Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic Oncology 2003;89(2):201-9.
13. Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics 2001;51(5):1246-55.
14. Creutzberg CL, Van Putten WL, Wárlám-Rodenhuis CC, Van den Bergh AC, De Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Journal of Clinical Oncology 2004;22(7):1234-41.
15. Creutzberg CL, Van Putten WLJ, Koper PCM, et al. Randomized trial on postoperative radiotherapy in pT1 endometrial carcinoma. International Journal of Gynecological Cancer. 1999; Vol. 9 Suppl 1:63 Abstract B5.
16. Look KY. Who benefits from radiotherapy in treatment of endometrial cancer and at what price? (comment on: Lancet. 2000 Apr 22;355(9213):1404-11). Lancet 2000;355(9213):1381-2.
17. Nout RA, Van de Poll-Franse LV, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with of without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. Journal of Clinical Oncology 2011;29(13):1692-700.
18. Scholten AN, Van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. International Journal of Radiation Oncology, Biology, Physics 2005;63(3):834-8.
19. Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, Van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. Journal of Clinical Oncology 2009;27(21):3547-56.
20. Nout RA, Smit VTHBM, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. The Lancet 2010;375(9717):816-23.
21. Soderini A, Anchezar JP, Sardi JE. Role of adjuvant radiotherapy (RT) in intermediate risk (1b G2-3-1C) endometrioid carcinoma (EC) after extended staging surgery (ESS). Preliminary reports of a randomised trial. International Journal of Gynecological Cancer 2003;13 (Supp 1), Abstract P0147:78.
22. Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. International Journal of Gynecological Cancer 2009;19(5):873-8.
23. Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma - a prospective randomised study. International Journal of Radiation Oncology, Biology, Physics 2011 Jun 13, issue Epub ahead of print. [PUBMED: 21676554]
24. Algan O, Tabesh T, Hanlon A, Hogan WM, Boente M, Lanciano RM. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II. endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 1996;35(5):925-33.
25. Atzinger A. Is there a benefit of postoperative pelvic irradiation in patients with FIGO stage I endometrial carcinoma?. Strahlenther Onkology 2001;177(2):112-3.
26. Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecologic Oncology 1995;57(2):138-44.
27. De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. European Journal of Cancer 1993;29A(8):1133-40. [MEDLINE: MEDLINE 93298438]
28. Dickler A. Puthawala MY, Thropay JP, Bhatnagar A, Schreiber G. Prospective multi-centre trial utilizing electronic brachytherapy for the treatment of endometrial cancer. Radiation Oncology 2010;5(1):67.
29. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in Stage 1 endometrium cancer. American Journal of Obstetrics and Gynecology 1985;151:1009-15.
30. Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk Stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial. International Journal of Radiation Oncology, Biology, Physics 1997;38(2):373-80. [MEDLINE: 1997227598]
31. Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris, N, Valensise H, et al. The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II. endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica 1994;73(8):652-7.
32. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III. trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2006;24(1):36-44.
33. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III. trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic Oncology 2007;107(2):177-85.
34. Haie-Meder C, Kramar A, Castaigne D, Lambin P, Bouzy J, Duvillard P, et al. Comparison of two low-dose rates in vaginal prophylactic pre-operative (PO) brachytherapy (BT) for stage I-II. endometrial carcinoma: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics 1995;32(Suppl1):223.
35. Haie-Meder C, Kramar A, El Boussairi H, Bouzy J, Briot E, Castaigne D, et al. Comparison of two low dose rates in vaginal prophylactic pre-operative brachytherapy for patients with stage I-II. endometrial carcinoma: long term results of a randomized trial. International Journal of Gynecological Cancer 2004;14:150-1.
36. Hogberg T, Signorelli M, De Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - results from two randomised studies. European Journal of Cancer 2010;46(13):2422-31.
37. Kang HJ, Sarin P, Lee HN, Saxena VS, Reddy S. Does treating whole abdomen improve survival in patients with clinically early stage endometrial and positive peritoneal cytology?. Gynecologic Oncology. 1992; Vol. 46:263-4, Abstract 16.
38. Kucera H, Vavra N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecologic Oncology 1990;38(1):99-104.
39. Maggi R, Cagnazzo G, Atlante G, Marinaccio M. Risk groups and adjuvant therapy in surgical staged endometrial cancer patients. A randomized multicentre study comparing chemotherapy with radiation therapy. International Journal of Gynecological Cancer. 1999; Vol. 9 Suppl 1:85 Abstract B73.
40. Maggi R, Cucchi L, Restelli C, Delzotti F, Frigoli A. Post surgical treatment of endometrial cancer: GICOG trial. International Journal of Gynecological Cancer. 1993; Vol. 3 Suppl 1:46 Abstract 166.
41. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer 2006;95:266-71.
42. Marchetti DL, Piver MS, Tsukada Y, Reese P. 100% Prevention of vaginal recurrence in patients with stage 1, grade 1 or 2 and <50% myometrial invasion treated by TAH BSO and postoperative vaginal radium. Proceedings of American Society of Clinical Oncology 4 March 1985;4:113. [: C-439]
43. Meerwaldt JH, Hoekstra CJ, Van Putten WL, Tjokrowardojo AS, Koper PC. Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors. International Journal of Radiation Oncology Biology, Physics 1990;18:299-304.
44. Orr JW Jr, Holimon JL, Orr PF. Stage I corpus cancer: Is teletherapy necessary?. American Journal of Obstetrics and Gynaecology 1997;176(4):777-89.
45. Marchetti DL, Piver MS, Tsukada Y, Reese P. 100% prevention of vaginal recurrence in patients with stage I, grade 1 or 2 and < 50% myometrial invasion treated by TAH BSO and postoperative vaginal radium. Proceedings of ASCO 1985;4:113.
46. Piver MS, Yazigi R, Blumenson L, Tsukada Y. A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma. Obstetrics and Gynaecology 1979;54(1):85-9.
47. Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock J, et al. from The Danish Endometrial Cancer Group (DEMCA). Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases. International Journal of Gynecological Cancer 1996;6(1):38-43.
48. Rubin SC, Barakat RR. Treatment of high-risk endometrial cancer should include post-operative radiation. International Journal of Gynecological Cancer 1995;5 Suppl 1:4 Abstract 13.
49. Sagae S. Randomized phase III. trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma. Proceedings of American Society of Clinical Oncology Annual Meeting. 2005.
50. Sorbe B, Straumits, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels. International Journal of Radiation Oncology, Biology, Physics 2005;62(5):1385-9.
51. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III. trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology 2008;108(1):226-33.
52. Takin S, Gungor M, Orta F, Oztuna D. Does postoperative radiotherapy provide any survival advantage over observation in stage IC endometrial cancer after comprehensive surgical staging?. European Journal of Obstetrics Gynecology and Reproductive Biology 2011;154(2):200-4.
53. Touboul E, Belkacemi Y, Buffat L, Deniaud Alexandre E, Lefranc JP, Lhuillier P, et al. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients. International Journal of Radiation Oncology, Biology, Physics 2001;50(1):81-97.
54. Weigensberg IJ. Preoperative radiation therapy in Stage I endometrial adenocarcinoma. II. Final report of a clinical trial. Cancer 1984;53(2):242-7.
55. Atahan IL, Ozyar E, Yildiz F, Ozyigit G, Genc M, Ulger S, et al. Vaginal high dose rate brachytherapy alone in patients with intermediate to high risk stage I endometrial carcinoma after radical surgery. Internationl Journal of Gynecological Cancer 2008;18:1294-9.
56. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncology 2011;12:353-60.
57. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz APM, et al. Carcinoma of the corpus uteri. Journal of Epidemiology and Biostatistics 2001;6(1):45-86.
58. Creutzberg C, Putten W, Koper P, Lybert M, Jobsen J, Warlam-Rodenhuis C, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics 2001;51(5):1246-55.
59. Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic Oncology 2003;89(2):201-9.
60. Creutzberg CL, Van Putten WL, Warlam-Rodenhuis CC, Van den Bergh AC, De Winter KA, Koper PC, et al. Outcome of High-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Journal of Clinical Oncology 2004;22(7):1234-41.
61. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. International Journal of Radiation Oncology, Biology, Physics 2011;15(81):3631-8.
62. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
63. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
64. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011; Vol. Available from www.cochrane-handbook.org.
65. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD003175.pub2]
66. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. The Lancet 2009;373(9658):125-36.
67. Kumar S, Shah JP, Bryant CS, Awonuga AO, Imudia AN, Ruterbusch JJ, et al. Second neoplasms in survivors of endometrial cancer: impact of radiation therapy. Gynecologic Oncology 2009;113(2):233-9.
68. McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, et al. Adjuvant vaginal brachytherapy alone for high risk localised endometrial cancer as defined by three major randomised trials of adjuvant pelvic radiation. Gynecologic Oncology 2010;116:404-7.
69. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecologic Oncology 2007;105(1):7-12.
70. Nout RA, Van de Poll-Franse LV, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. Journal of Clinical Oncology 2011;29(13):1692-700.
71. Panici PB, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. Journal of the National Cancer Institute 2008;100(23):1707-16.
72. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
73. Creutzberg CCL. Randomized Phase III. Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3. Clinical Trials Register Ongoing trial; Vol. NCT00411138.
74. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
75. Scholten AN, Van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. International Journal of Radiation Oncology, Biology, Physics 2005;63(3):834-8.
76. Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstetrics and Gynecology International 2010: 749579; Vol. Epub 2010 Feb 2.
77. Kong AA, Johnson N, Cornes P, Simera I, Collingwood M, Williams C, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD003916.pub2]
78. Kong A, Simera I, Collingwood M, Williams C, Kitchener H. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Annals of Oncology 2007;18:1595-604.